


# **NIDA HIV Research Program**

## **Supporting Research at the Intersection of HIV and Substance Use**



National Institute  
on Drug Abuse

*Advancing Addiction Science*

## NIDA's HIV Research Priority Areas

NIDA supports research at the intersection of substance use, HIV, and related comorbidities to:

- 1 Prevent HIV infections and transmission
- 2 Increase understanding of HIV infection
- 3 Improve health outcomes
- 4 Accelerate scientific discoveries

## Signature HIV Research Initiatives

### Avant-Garde Program for HIV and Substance Use Disorder Research (DP1)

PAR-23-269

The Avant-Garde Award Program supports scientists of exceptional creativity proposing cutting-edge, transformative research at the nexus of HIV and substance use disorder.

*Requires 35% research effort. Five-page essay. Preliminary data not required. Applications due August 14, 2024.*



### Avenir Award Program for Research on Substance Use Disorders and HIV (DP2)

PAR-23-125

The Avenir Award Program supports early stage investigators (ESI) with innovative research ideas about science at the intersection of HIV and substance use.

*Requires 25% research effort. For ESIs only. Preliminary data not required. Applications due August 15, 2024.*



### High Priority HIV and Substance Use Research

RFA-DA-22-040 (R01) / RFA-DA-22-060 (RM1)

The High Priority HIV Award Program supports innovative projects to open new avenues for the prevention, treatment and cure of HIV among people who use drugs.

*R01 award. High priority/High impact research topics. Requires preliminary data. Applications due August 1, 2024.*

*RM1 award. Team science initiative requiring interdisciplinary effort. Requires team of three to six principal investigators at 20% research effort each. Applications due August 15, 2024.*



## Additional Funding Opportunities for HIV Research at NIDA

In addition to the signature research initiatives, NIDA offers many other funding opportunities at the intersection of HIV and substance use.

- Addressing HIV in Highest Risk Sexual and Gender Minorities (RFA-DA-25-001 & RFA-DA-25-002)
- Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (RFA-DA-25-007 & RFA-DA-25-008)
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (RFA-DA-25-019 & RFA-DA-25-059)
- Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (RFA-DA-25-018)
- Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (RFA-DA-24-001)
- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (RFA-DA-25-009 & RFA-DA-25-010)
- Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (RFA-DA-25-014)
- Notice of Special Interest (NOSI): Saving Lives: Integrating Overdose Education and Naloxone Distribution (OEND) into HIV Prevention and Care Settings for People Who Use Addictive Substances (NOT-DA-25-031)
- Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (RFA-DA-23-008)
- Targeting Inflammasomes in HIV and Substance Use (RFA-DA-25-012 & RFA-DA-25-013)

Scan for a complete list  
of HIV-related funding  
opportunities.



## Participate in our Quarterly HIV Seminars!

The NIDA HIV Seminars feature front-line research at the intersection of HIV and substance use. Visit our HRP Meetings of Interest page to check out past seminars and to register now for our upcoming events.



## Join the NIDA HIV Research Program Contact List!

Sign up for the NIDA HRP contact list to receive our monthly HIV newsletter on events, funding opportunities, and research updates at the intersection of HIV and substance use.



## Contact the HIV Research Program!

**Dr. Redonna Chandler, Director**

✉ [Redonna.Chandler@nih.gov](mailto:Redonna.Chandler@nih.gov)

**Dr. Vasundhara Varthakavi, Associate Director**

✉ [Vasundhara.Varthakavi@nih.gov](mailto:Vasundhara.Varthakavi@nih.gov)

